Utility of 18FDOPA PET/MRI for Focal Hyperinsulinism

Part of paid clinical trials in St Louis, Missouri.

Sponsor
Washington University School of Medicine
Study ID
NCT05088798
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

  • Hyperinsulinism

Eligibility Criteria

Sex
ALL
Age
N/A - N/A
Healthy Volunteers
Not accepted

Interventions

  • 18F-Fluoro Dopa PET/MRI Imaging — DRUG
    The purpose of this research study is to provide access to an imaging study of the pancreas that uses 6-\[18F\]-Fluoro-L-3,4,-dihydroxyphenylalanine (18F-DOPA)positron emission tomography (PET) and assess the accuracy of this 18F-DOPA-PET/MRI test on distinguishing what part of the pancreas is affected in patients with Hyperinsulinism.

Study Details

The purpose of the study is to provide access to 18F-DOPA PET to patients at Washington University and assess the utility of 18F-DOPA PET/MRI as a preoperative tool to detect and localize focal lesions in the pancreas that are causing hyperinsulinism.

Key Dates

Start date
Sep 10, 2020
Status verified
Dec 2025
Primary completion
Jan 1, 2030
Completion
Jan 1, 2030

Study Design

Enrollment
100 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC

Arms

  • Experimental: 18F-Fluoro Dopa Imaging
    single arm

Primary Outcome Measure

Increase Access to 18F-DOPA PET/MRI (or PET/CT) for patients with HI who failed medical therapy [ Time Frame: one year ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Washington UniversitySt LouisMissouri63110
Ana M Arbelaez, MD
[email protected]
314-454-6051
Maria R Ponisio, MD (SUB_INVESTIGATOR)

Find similar trials in St Louis, MO

By research site
Washington University· St Louis, MO

Related Studies